Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 345 - 352 of 12092 results

New York Proposes Expansion of Disclosure Requirements for Material Health Care Transactions
February 14, 2025| Blog| Viewpoint

Trump Actions Could Undermine EEOC AI Bias Efforts
February 13, 2025| News

Operationalizing the Medicare Prescription Payment Plan and Medicare Inflation Rebate Program
February 13, 2025| Article| Viewpoint

The Future of the Medicare Drug Price Negotiation Program
February 13, 2025| Article| Viewpoint

A Circuit Win and the End of Chevron Deference Could Shift Tides in Drug Price Negotiation Program Challenges
February 13, 2025| Article| Viewpoint

Duplicate Discounts Between the 340B Program & Medicare Drug Price Negotiation Program
February 13, 2025| Article| Viewpoint

The IRA in 2025: The Future of Medicare Part D
February 13, 2025| Article| Viewpoint

From the Desk of ML Strategies: The Medicare Drug Price Negotiation Program Under the Second Trump Administration
February 13, 2025| Article| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
